Scottish Medicines Consortium gives the green light to three products

12 October 2015
lots-of-pills-big

The Scottish Medicines Consortium (SMC) has made decisions on three products.

Xultophy (insulin degludec/liraglutide) from Novo Nordisk (NOV: N), Zytiga (abiraterone acetate) from Janssen, a unit of Johnson & Johnson (NYSE: JNJ), and Xofigo (radium-223 dichloride) from Bayer (BAYN: DE)) have all been given the green light by the SMC.

Xultophy is recommended for use in adults with type 2 diabetes, uncontrolled on basal insulin analogues and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin to obtain glucose control.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical